Cellectar Biosciences (CLRB) Biotech Showcase 2025 summary

Company overview and platform

• Focuses on oncology, specifically drug conjugates and radiopharmaceuticals using a phospholipid ether platform for targeted delivery to tumor cells.

• Platform enables conjugation of diverse payloads, including radioisotopes, small molecules, biologics, and nucleic acids, with validated activity in preclinical and clinical settings.

• Targets lipid rafts, which are ubiquitously present in tumor cells, allowing for broad applicability across cancer types.

• Demonstrated ability to deliver payloads into protected domains like the CNS, enabling treatment of difficult-to-reach tumors.

Lead asset: iopofosine I-131

• Completed a successful phase II study in Waldenstrom's macroglobulinemia, showing a major response rate of over 58% and an overall response rate of nearly 84%.

• Disease control rate reached 98.2%, with only one non-responder; safety profile was clean except for expected cytopenias.

• Regulatory pathway involves a confirmatory randomized controlled trial of about 100 patients, with anticipated approval in 12–18 months.

• Addresses a rare orphan disease with significant unmet need, especially for patients refractory to existing therapies.

• Demonstrated efficacy across various refractory and genetically diverse patient populations, including those with p53 mutations.

Pipeline and early-stage programs

• Pipeline includes assets targeting multiple myeloma, DLBCL, mantle cell, marginal zone, pediatric high-grade glioma, and indolent diseases.

• CLR 121225 and CLR 121125 are advancing into phase I studies for pancreatic and triple-negative breast cancer, respectively.

• Alpha and Auger emitter programs show strong preclinical efficacy in pancreatic, prostate, and triple-negative breast cancer models.

• Phase I dose escalation studies for these programs are planned for the first half of the year.